{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:42Z","timestamp":1790832462980,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH-Fogarty","award":["D43TW009127"],"award-info":[{"award-number":["D43TW009127"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40360-019-0313-y","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:06:52Z","timestamp":1558609612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Workineh","family":"Shibeshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi N.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addisu","family":"Admasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemseged Beyene","family":"Berha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenebe","family":"Negash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getnet","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"3","key":"313_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). 2014;3(3):317\u201340.","journal-title":"Antibiotics (Basel)"},{"key":"313_CR2","unstructured":"World Health Organization, Global Tuberculosis Report 2018, \n                    http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?ua=1\n                    \n                  . Accessed 10 Feb 2019."},{"key":"313_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/2047-2994-3-31","volume":"3","author":"F Biadglegne","year":"2014","unstructured":"Biadglegne F, Ulrich S, Rodloff AC. Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care. Antimicrob Resist Infect Control. 2014;3:31.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"6","key":"313_CR4","first-page":"145","volume":"3","author":"C Gilpin","year":"2016","unstructured":"Gilpin C, Korobitsyn A, Weyer K. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther Adv Infect Dis. 2016;3(6):145\u201351.","journal-title":"Ther Adv Infect Dis"},{"key":"313_CR5","volume-title":"Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update","author":"WHO","year":"2016","unstructured":"WHO. Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization; 2016."},{"key":"313_CR6","volume-title":"Rapid Communication Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)","author":"World Health Organization","year":"2018","unstructured":"World Health Organization, Rapid Communication Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). 2018 \n                    https:\/\/www.who.int\/tb\/publications\/2018\/WHO_RapidCommunicationMDRTB.pdf?ua=1"},{"key":"313_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2334-14-542","volume":"14","author":"C Modongo","year":"2014","unstructured":"Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014;14:542.","journal-title":"BMC Infect Dis"},{"key":"313_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ejcdt.2015.05.011","volume":"64","author":"M Awad Tag El-Din","year":"2015","unstructured":"Awad Tag El-Din M, Atef Abd-El Halim H, Mahmoud El-Tantawy A. Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009. Egypt J Chest Dis Tuberc. 2015;64:657\u201364.","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"313_CR9","first-page":"622","volume":"6","author":"P de Jager","year":"2002","unstructured":"de Jager P, van Altena R. Hearing loss and nephrotoxicity in long term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc LungDis. 2002;6:622\u20137.","journal-title":"Int J Tuberc LungDis"},{"key":"313_CR10","doi-asserted-by":"publisher","unstructured":"Kros CJ, Steyger PS. Aminoglycoside- and cisplatin induced ototoxicity: mechanisms and Otoprotective strategies. Cold Spring Harb Perspect Med. 2018;17. \n                    https:\/\/doi.org\/10.1101\/cshperspect.a033548\n                    \n                  .","DOI":"10.1101\/cshperspect.a033548"},{"key":"313_CR11","doi-asserted-by":"publisher","first-page":"937861","DOI":"10.1155\/2011\/937861","volume":"2011","author":"ME Huth","year":"2011","unstructured":"Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861.","journal-title":"Int J Otolaryngol"},{"issue":"4","key":"313_CR12","first-page":"320","volume":"66","author":"JA Seddon","year":"2013","unstructured":"Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Inf Secur. 2013;66(4):320\u20139.","journal-title":"J Inf Secur"},{"key":"313_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fncel.2017.00308","volume":"11","author":"M Jiang","year":"2017","unstructured":"Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced Cochleotoxicity: a review. Front Cell Neurosci. 2017;11:308.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"313_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1117\/1.JBO.24.5.051403","volume":"24","author":"DE Desa","year":"2018","unstructured":"Desa DE, Nichols MG, Smith HJ. Aminoglycosides rapidly inhibit NAD(P) H metabolism increasing reactive oxygen species and cochlear cell demise. J Biomed Opt. 2018;24(5):1\u201314.","journal-title":"J Biomed Opt"},{"key":"313_CR15","doi-asserted-by":"publisher","unstructured":"Wrze\u015bniok D, Rok J, Beberok A, Rzepka Z, Respondek M, Pilawa B, Zdybel M, Delijewski M, Buszman E. Kanamycin induces free radicals formation in melanocytes: an important factor for aminoglycosides ototoxicity. J Cell Biochem. 2018. \n                    https:\/\/doi.org\/10.1002\/jcb.26817\n                    \n                  .","DOI":"10.1002\/jcb.26817"},{"issue":"5","key":"313_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"M Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq M, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"313_CR17","first-page":"1373","volume":"9","author":"T Torun","year":"2005","unstructured":"Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373\u20137.","journal-title":"Int J Tuberc Lung Dis."},{"key":"313_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2165\/00019053-199915050-00003","volume":"15","author":"TJ White","year":"1999","unstructured":"White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15:445\u201358.","journal-title":"Pharmacoeconomics."},{"key":"313_CR19","volume-title":"Multidrug and extensively drug-resistant TB(M\/XDR-TB) - 2010 global report on surveillance and response","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Multidrug and extensively drug-resistant TB(M\/XDR-TB) - 2010 global report on surveillance and response. Geneva: World Health Organization; 2010."},{"key":"313_CR20","unstructured":"Federal Ministry of Health. Guideline for program and clinical Management of Drug Resistant Tuberculosis. Ethiopia: Federal Ministry of Health of Ethiopia; 2009."},{"key":"313_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4236\/jtr.2014.23018","volume":"2","author":"H Bezu","year":"2014","unstructured":"Bezu H, Seifu D, Yimer G, Mebrhatu T. Prevalence and risk factors of adverse drug reactions associated multidrug resistant tuberculosis treatments in selected treatment centers in Addis Ababa Ethiopia. J Tuberc Res. 2014;2:144\u201354.","journal-title":"J Tuberc Res"},{"issue":"11","key":"313_CR22","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1086\/420742","volume":"38","author":"CA Peloquin","year":"2004","unstructured":"Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538\u201344.","journal-title":"Clin Infect Dis"},{"key":"313_CR23","unstructured":"World Health Organization (WHO). Report of an informal consultation onstrategies for prevention of hearing impairment from ototoxic drugs. Geneva: World Health Organization; 1994."},{"key":"313_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1808-8694(15)31053-3","volume":"72","author":"LCB Jacob","year":"2006","unstructured":"Jacob LCB, Aguiar FP, Tomiasi AA, Tschoeke SN, De Bitencourt RF. Auditorymonitoring in ototoxicity. Braz J Otorhinolaryngol. 2006;72:836\u201344.","journal-title":"Braz J Otorhinolaryngol"},{"key":"313_CR25","first-page":"3569018","volume":"12","author":"TH Leveri","year":"2019","unstructured":"Leveri TH, Lekule I, Mollel E, Lyamuya F, Kilonzo K. Predictors of treatment outcomes among multidrug resistant tuberculosis patients in Tanzania. Tuberc Res Treat. 2019;12:3569018.","journal-title":"Tuberc Res Treat"},{"key":"313_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40360-015-0036-7","volume":"16","author":"EL Sagwa","year":"2015","unstructured":"Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis-treatment under programmatic conditions ina Namibian retrospective cohort. BMC Pharmacol Toxicol. 2015;16:36.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"313_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/mdr.2013.0145","volume":"20","author":"K Wang","year":"2014","unstructured":"Wang K, Chen S, Wang X, Zhong J, Wang X, Huai P, Wu L, Wang L, Jiang S, Li J, Peng Y, Yao H, Ma W. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China. Microb Drug Resist. 2014;20(4):294\u2013300.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"313_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12879-018-3401-5","volume":"18","author":"S Eshetie","year":"2018","unstructured":"Eshetie S, Alebel A, Wagnew F, Geremew D, Fasi A, Sack U. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients\u2019 data analysis for outcome and effectiveness of the current regimens. BMC Infect Dis. 2018;18(1):486.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"313_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40794-018-0065-5","volume":"14","author":"T Girum","year":"2018","unstructured":"Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018;14(4):5.","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"7","key":"313_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/1389200218666171108154419","volume":"19","author":"H Wu","year":"2018","unstructured":"Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19(7):559\u201367.","journal-title":"Curr Drug Metab"},{"key":"313_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/ki.1988.83","volume":"33","author":"HD Humes","year":"1988","unstructured":"Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900.","journal-title":"Kidney Int"},{"key":"313_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-100-3-352","volume":"100","author":"RD Moore","year":"1984","unstructured":"Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352.","journal-title":"Ann Intern Med"},{"issue":"11","key":"313_CR33","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1517\/17425255.2015.1083011","volume":"11","author":"GC Gobe","year":"2015","unstructured":"Gobe GC, Coombes JS, Fassett RG, Endre ZH. Biomarkers of drug-induced acute kidney injury in the adult. Expert Opin Drug Metab Toxicol. 2015;11(11):1683\u201394.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"313_CR34","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2174\/1389200217666160406115959","volume":"17","author":"S Fusco","year":"2016","unstructured":"Fusco S, Garasto S, Corsonello A, Vena S, Mari V, Gareri P, Ruotolo G, Luciani F, Roncone A, Maggio M, Lattanzio F. Medication-induced nephrotoxicity in older patients. Curr Drug Metab. 2016;17(6):608\u201325.","journal-title":"Curr Drug Metab"},{"key":"313_CR35","doi-asserted-by":"publisher","unstructured":"Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, Chis Ster I, Harrison TS. Adverse effects and choice between the injectable agents amikacin and Capreomycin in multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(9). \n                    https:\/\/doi.org\/10.1128\/AAC.02586-16\n                    \n                  .","DOI":"10.1128\/AAC.02586-16"},{"issue":"1","key":"313_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119\u201326.","journal-title":"Curr Pharm Des"},{"key":"313_CR37","doi-asserted-by":"publisher","unstructured":"Hong H, Dooley KE, Starbird LE, Francis HW, Farley JE. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment. Arch Toxicol. 2019. \n                    https:\/\/doi.org\/10.1007\/s00204-019-02407-8\n                    \n                  .","DOI":"10.1007\/s00204-019-02407-8"},{"issue":"12","key":"313_CR38","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","volume":"70","author":"D Meressa","year":"2015","unstructured":"Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia -an observational cohort study. Thorax. 2015;70(12):1181\u20138.","journal-title":"Thorax."},{"issue":"2","key":"313_CR39","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/MJT.0b013e3181c0806d","volume":"18","author":"P Baghaei","year":"2011","unstructured":"Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV, Mansouri D, Farnia P, Masjedi M, Velayati A. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther. 2011;18(2):e29\u201334.","journal-title":"Am J Ther"},{"issue":"5","key":"313_CR40","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1097\/MJT.0000000000000421","volume":"25","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Javaid A, Syed Sulaiman SA, Afridi AK. Zainab khan AH. Occurrence, management, and risk factors for adverse drug reactions in multidrug resistant tuberculosis patients. Am J Ther. 2018;25(5):e533\u201340.","journal-title":"Am J Ther"},{"issue":"6","key":"313_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.5588\/ijtld.17.0830","volume":"22","author":"H Hong","year":"2018","unstructured":"Hong H, Budhathoki C, Farley JE. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int J Tuberc Lung Dis. 2018;22(6):667\u201374.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"12","key":"313_CR42","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.5588\/ijtld.16.0953","volume":"21","author":"EL Sagwa","year":"2017","unstructured":"Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Mengistu A, Mekonen TT, Leufkens HGM, Mantel-Teeuwisse AK. Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents. Int J Tuberc Lung Dis. 2017;21(12):1245\u201350.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"313_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0970-2113.197118","volume":"34","author":"R Prasad","year":"2017","unstructured":"Prasad R, Gupta N, Banka A. Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: a priority to improve treatment outcome. Lung India. 2017;34(1):1\u20132.","journal-title":"Lung India"},{"issue":"11","key":"313_CR44","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1080\/14740338.2016.1223623","volume":"15","author":"AJ Garcia-Prats","year":"2016","unstructured":"Garcia-Prats AJ, Schaaf HS, Hesseling AC. The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(11):1491\u2013500.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"313_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38(3):253\u201369.","journal-title":"Drug Saf"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-019-0313-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0313-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T19:15:55Z","timestamp":1590088555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-019-0313-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1186\/s40360-019-0313-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval of the study protocol was obtained from all concerned bodies including from Institutional Review Board of College of Health Sciences of Addis Ababa University (Ref: 002\/2017), Armauer Hanson Research Institute (AHRI)-All African Leprosy Rehabilitation and Training Center (ALERT) Ethics Review Committee (AAERC) (Ref: P005\/17 and Emory University Institutional Review Board (Ref: IRB 00093720). The confidentiality of data was maintained via ethical training of data collectors, safe storage of collected data, and finally de-identifying of personal information prior to data analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"31"}}